Pharmaceutical Industry 20 – 26 Apr: Ft Transgene and Bayer
- Transgene has completed patient randomisation in the phase 2 part of its phase 1/2 TG4050 trial in head and neck cancer.
- Bayer has secured MHRA approval in the UK for Kerendia (finerenone) in adults with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above.
A Week of Meaningful Progress for Transgene and Bayer
Two important developments from Transgene and Bayer have underlined the pace and breadth of innovation currently moving through the pharmaceutical industry.
On one side, Transgene has reached a notable clinical milestone with its individualised cancer vaccine TG4050. On the other, Bayer has received UK regulatory approval for Kerendia, expanding treatment options for a large and often underserved heart failure population.
While the two updates sit in different therapeutic areas, they are linked by a common thread: both point to a pharmaceutical landscape increasingly focused on smarter targeting, stronger evidence and better outcomes for patients whose needs have not always been fully met by conventional treatment pathways.
Transgene Advances TG4050 in Head and Neck Cancer
Transgene’s latest announcement centres on the completion of patient randomisation in the phase 2 part of its ongoing phase 1/2 clinical trial evaluating TG4050. The therapy is being developed as an adjuvant treatment for head and neck cancer, specifically to help prevent relapse after surgery and adjuvant chemoradiotherapy.
The randomised multicentre study is comparing TG4050 as a single agent against watchful waiting in patients with locoregionally advanced HPV-negative head and neck cancer.
That alone makes the programme worth watching closely. This is a difficult disease setting, and the ability to reduce the risk of recurrence after primary treatment remains a major goal in oncology.
The study has now enrolled 38 patients in the phase 2 cohort. Top-line two-year disease-free survival data are expected by the end of the first quarter of 2028, giving the programme a clear next milestone.
Before then, the company plans to release first immunological data in the second half of 2026, while further three-year follow-up from the phase 1 cohort is expected in mid-2026.
Why TG4050 Matters
TG4050 has been created using Transgene’s myvac platform and is designed as an individualised neoantigen therapeutic vaccine.
In practical terms, that means it is built to generate a targeted immune response tailored to the patient, with the aim of helping the immune system recognise and fight residual cancer cells that could otherwise lead to relapse.
That is part of what makes the programme especially interesting. Therapeutic vaccines in oncology have long attracted attention, but the field has increasingly shifted towards more personalised approaches, where treatment is shaped around the molecular features of the tumour rather than a one-size-fits-all model.
Transgene has described the completion of randomisation as a significant step forward for both TG4050 and the wider myvac platform.
The company’s Chairman and CEO said the milestone confirms the expected timing of the primary endpoint readout by the end of Q1 2028 and also highlighted the importance of the patients, investigators and site personnel helping move the programme forward.
The wider message is clear: TG4050 is not being positioned as a speculative concept, but as a carefully advancing immunotherapy with defined clinical checkpoints ahead.
Encouraging Early Signals Build Credibility
The programme is also supported by encouraging phase 1 data. Transgene has reported that TG4050 was well tolerated and induced durable immune responses, with all treated patients remaining disease-free at two years.
Those findings are early, and oncology development always demands caution, but they provide a credible foundation for the phase 2 portion of the study.
That matters in a competitive pharmaceutical environment where promising science is not enough on its own. Programmes need to show tolerability, immune activity and a convincing signal that they may translate into meaningful patient benefit.
TG4050 now moves into its next stage with that early backing in place.
Bayer Wins UK Approval for Kerendia
Alongside Transgene’s oncology progress, Bayer has received MHRA approval for Kerendia, also known as finerenone, for adults in the United Kingdom with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above.
The decision is significant because it covers both heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction.
Together, those two phenotypes account for around half of all heart failure cases in the UK. In other words, this is not a niche regulatory event. It touches a very large patient group within everyday NHS care.
Heart failure affects more than one million people in the UK, and outcomes remain especially poor for those with preserved ejection fraction. For clinicians, this has been an area marked by complexity, limited treatment options and persistent unmet need.
A New Option for a Historically Underserved Population
A Consultant Cardiologist at Manchester University NHS Foundation Trust described heart failure with preserved ejection fraction and heart failure with mildly reduced ejection fraction as among the most challenging forms of heart failure to manage in routine clinical practice.
They pointed to high rates of hospitalisation and mortality, while also noting that treatment options for preserved ejection fraction have, until relatively recently, been limited and offered few proven benefits.
That is what gives the MHRA approval broader weight. Kerendia now becomes an additional licensed option within current heart failure management pathways for a large patient population that has historically lacked strong therapeutic choices.
The approval is based on the phase 3 FINEARTS-HF study, which enrolled 6,001 adults with symptomatic heart failure and an ejection fraction of at least 40%.
In the trial, finerenone reduced the risk of the composite primary endpoint of cardiovascular death and total heart failure events by 16 per cent over a median follow-up of 32 months compared with placebo. The benefits were consistent across all pre-specified subgroups, and the treatment was generally well tolerated.
Crucially, finerenone is the first non-steroidal mineralocorticoid receptor antagonist to show definitive benefit in a phase 3 study in this particular patient population. That gives Bayer not just a regulatory win, but a scientifically meaningful one.
What This Means for Pharmaceutical Manufacturing and Production
For pharmaceutical manufacturing and pharmaceutical production, these developments are important for different reasons.
In Transgene’s case, TG4050 reflects the growing industrial shift towards personalised medicines, which place greater demands on manufacturing precision, flexible production systems and advanced quality control.
Individualised therapies require pharmaceutical producers to think beyond traditional scale alone and instead build systems capable of handling complexity, customisation and tight turnaround times.
Bayer’s Kerendia approval points to another side of the equation: the continued importance of large-scale, evidence-backed medicines that can be integrated into established healthcare pathways and serve broad patient populations.
This kind of approval supports the commercial and manufacturing case for reliable, scalable production of therapies with proven cardiovascular benefit.
Taken together, the two stories show that pharmaceutical production is no longer moving in just one direction. The industry is having to support both highly personalised next-generation treatments and major mainstream therapies for widespread chronic disease.
That balance will shape investment, infrastructure and manufacturing strategy across the sector for years to come.
Precision and Scale Are Defining the Next Chapter
There is something telling in the contrast between these announcements. Transgene is pushing ahead with an individualised cancer vaccine designed around precision immune targeting. Bayer is broadening access to an approved therapy for one of the UK’s largest chronic disease burdens.
One story is about tailored intervention after cancer treatment. The other is about expanding options in a difficult cardiovascular setting affecting hundreds of thousands of people.
Yet both are emblematic of a pharmaceutical industry under pressure to be more effective, more evidence-led and more relevant to real clinical need.
Whether through customised immunotherapy or improved heart failure care, the expectation is the same: treatments must do more than sound promising. They must show they can change outcomes.
Conclusion
Taken together, the latest updates from Transgene and Bayer offer a strong snapshot of where the pharmaceutical industry is heading.
Transgene’s progress with TG4050 highlights the promise of personalised immunotherapy and the growing confidence behind targeted, patient-specific cancer treatment. Bayer’s MHRA approval for Kerendia, meanwhile, marks an important step forward for heart failure care in the UK, particularly for patients who have long faced limited treatment options.
Both developments carry weight not only for clinicians and patients, but also for the wider pharmaceutical sector. They reflect an industry being shaped by two powerful forces at once: precision and scale.
Whether through bespoke therapeutic vaccines or widely deployable cardiovascular medicines, the message is the same. Pharmaceutical innovation is becoming more ambitious, more practical and, increasingly, more closely aligned with the realities of patient care.
News Credits:
Transgene completes randomisation in phase 2 trial of tg4050
Bayer wins MHRA approval for Kerendia in heart failure
Things you may also like: